“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

The global medtech company is also looking to expand its organ transplant and ECMO portfolios.

James Min, MD, Cleerly's founder and CEO, changed careers to address what he saw as a major unmet need in cardiology.

Sanofi's Merilog is a new biosimilar substitute for Novo Nordisk’s NovoLog. It can be used to treat adult and pediatric patients with type 1 and type 2 diabetes.

Aspartame, the artificial sweetener commonly found in diet sodas and sugar-free snacks, may do significant harm to a person’s cardiovascular system.

Sotagliflozin, a dual SGLTI and SGLT2 inhibitor, can significantly reduce the risk of adverse cardiovascular events in patients with type 2 diabetes, CKD and additional cardiovascular risk factors, according to a new study of more than 10,000 patients. 

The median follow-up period was more than nine years, allowing researchers to compare long-term outcomes after both CABG and PCI. 

Researchers used advanced AI to see if any FDA-approved medications could potentially reverse one of the mutations behind dilated cardiomyopathy. Risedronate, a popular osteoporosis medication, is the one candidate that got the job done.

Johnson & Johnson MedTech has resumed the U.S. rollout of its Varipulse PFA system, sharing new warnings to help physicians.